<DOC>
	<DOCNO>NCT01813539</DOCNO>
	<brief_summary>The purpose study determine recommend Phase 2 dose ARGX-110 , antibody bind CD70 , patient advance malignancy .</brief_summary>
	<brief_title>Phase 1b Study ARGX-110 Patients With Advanced Malignancies</brief_title>
	<detailed_description>Phase 1 study conduct patient whose tumor express target interest . PK , PD , biomarkers determine support dose selection .</detailed_description>
	<criteria>Age ≥18 year . Written inform consent prior studyrelated procedure , willing able comply protocolspecified procedure schedule evaluation . Histological diagnosis CD70 antigen positive malignancy refractory , relapse standard therapy . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Adequate haematological , hepatic , renal function ( absolute neutrophil count ( ANC ) &gt; 1.0 x 109/L ; haemoglobin &gt; 90 g/L ; platelet count ≥ 75 x 109/L ; total bilirubin ≤ 1.5 x upper limit normal [ ULN ] ; alanine transaminase [ ALT ] ≤ 3 x ULN ≤ 5 x ULN patient liver metastasis ; serum creatinine ≤ 1.5 x ULN ) . Prior allogeneic bone marrow transplantation . History clinical evidence neoplastic central nervous system ( CNS ) involvement . History another primary malignancy remission least 1 year . Systemic glucocorticoid administration dose great physiological replacement within 4 week ARGX110 first dose administration . Major surgery within 4 week ARGX110 first dose administration . Prior chemotherapy , biological therapy , radiation therapy curative intent , experimental therapy within 4 week ARGX110 first dose administration . Unresolved grade 3 4 toxicity prior therapy , include experimental therapy . Active , untreated viral , bacterial , systemic fungal infection . History human immunodeficiency virus ( HIV ) infection , persistent hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) infection . Any clinical finding , include psychiatric behavioral problem , , opinion Investigator , preclude patient safely participate study . Childbearing potential unless use adequate measure contraception . Pregnancy lactation . History hypersensitivity recombinant protein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>malignancy</keyword>
</DOC>